|
|
Article: Aphton Reports Activity of IGN101 in Reducing Disseminating Tumor Cells From Patients With Epithelial Cancers.
- Article from:
- Business Wire
- Article date:
- May 16, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PHILADELPHIA -- Early Data Demonstrated Reduction of Disseminating Tumor in Patients With Cancers of the Colon, Breast and Ovary
Aphton Corporation (NASDAQ:APHT) announced today that preliminary data from an ongoing open-label, multicenter Phase II clinical trial with IGN101 in patients with several types of solid tumors was presented on Sunday at the 2005 Annual Meeting of the American Society for Clinical Oncology (ASCO) in Orlando, Florida.
Investigators presented early data from an ongoing single arm study of IGN101 in patients with various solid tumors. The study, which is intended to accrue 45 patients, has enrolled 17 patients to date. The primary ...